REGN
NASDAQ · Biotechnology
Regeneron Pharmaceuticals
$714.89
+5.79 (+0.82%)
REGN News6 articles
Bayer's $2.45B Perfuse Buy Aims to Revitalize Eye Drug Pipeline
Bayer acquires Perfuse Therapeutics for up to $2.45 billion to secure Phase II eye drug PER-001, aiming to bolster its ophthalmology unit as Eylea sales slip.
Regeneron Q1 Results Top Estimates, Eylea Challenges Loom
Regeneron reported strong Q1 results with revenue up 19% and earnings above estimates, but Eylea sales declined and an FDA delay on a new syringe manufacturer weighs on shares.
Regeneron Stock Rises on Drug Pricing Deal, Free Gene Therapy Offer
Regeneron shares gained 2.6% Thursday following a drug-pricing pact with the U.S. and a plan to offer its new gene therapy Otarmeni at no cost. Analysts remain optimistic ahead of Q1 results.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
Pfizer Shares Dip Amid Vaccine Policy Clarity, Eczema Drug Progress
Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.
Pfizer's Eczema Candidate Tilrekimig Advances, Eyes Dupixent Rivalry
Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.